JY BioMedical and Taipei Medical University Launch Collaborative Research on Gamma-Delta T Cell Therapy for Liver Cancer
- 博翔(Benjamin) 張
- Jan 29
- 2 min read
JY BioMedical is thrilled to announce a groundbreaking partnership with Taipei Medical University (TMU) to advance research on gamma-delta (γδ) T cell therapy as a novel treatment for hepatocellular carcinoma (HCC), a leading cause of cancer-related deaths worldwide. This industry-academia collaboration, set to begin on March 1, 2025, seeks to address the urgent need for innovative therapies for liver cancer, particularly for advanced-stage patients with limited treatment options.
The joint project, titled "Evaluating the Potential Efficacy of Gamma-Delta (γδ) T Cell Therapy on Hepatocellular Carcinoma," will run until February 28, 2026. By combining TMU’s research excellence and JY BioMedical’s cutting-edge cell therapy technology, the collaboration aims to explore the therapeutic potential of γδ T cells in overcoming the challenges posed by the immunosuppressive tumor microenvironment of HCC.
Key Objectives of the Collaboration Include:
In Vitro Studies: Investigating the cytotoxic effects of γδ T cells on HCC cell lines using advanced analytical methods such as caspase activation and real-time imaging.
In Vivo Studies: Testing the efficacy of γδ T cells in xenograft mouse models to evaluate tumor growth suppression and survival benefits.
Therapeutic Advancement: Demonstrating γδ T cells' ability to bypass the immunosuppressive barriers of liver cancer, paving the way for innovative immunotherapy solutions.
Dr. Tsung-Yi Hsu, Professor of Neuromedicine at Taipei Medical University and Principal Investigator of the project, expressed enthusiasm for the collaboration: "This collaboration is an exciting opportunity to combine scientific rigor and innovative technologies to address one of the most pressing challenges in oncology. Our goal is to deliver meaningful advancements in liver cancer treatment.”
Dr. Benjamin Zhang, Chief Medical Officer of JY BioMedical, added:
"Liver cancer remains one of the deadliest cancers globally, and this partnership with TMU represents a significant step forward in addressing this unmet medical need. Together, we aim to bring γδ T cell therapy closer to clinical reality."
With this collaboration officially starting in March 2025, JY BioMedical and TMU are at the forefront of exploring new frontiers in liver cancer immunotherapy, reaffirming their commitment to advancing science and improving patient outcomes.
About JY BioMedical
JY BioMedical is a biotechnology company at the forefront of developing transformative cell-based therapies. The company focuses on harnessing the power of innovative immunotherapy technologies to improve patient outcomes in cancer and immune-related diseases.
About Taipei Medical University
Taipei Medical University is a globally recognized institution known for its cutting-edge medical research and academic excellence. TMU’s Neuromedicine Program is dedicated to exploring innovative therapies for some of the most challenging diseases.
For further information, please contact: service@jy-biomed.com
Commenti